Wellgistics Health Targets Expansion into $6.3 Billion Mental Health Software Market with Strategic Investment into Stealth Mental Health AI Startup
Rhea-AI Summary
Wellgistics Health (NASDAQ:WGRX) completed a strategic investment in a San Francisco mental health AI startup and is expanding patient‑engagement efforts tied to its EinsteinRx™ AI and PharmacyChain™ platform.
The move strengthens partnerships with Tollo Health and NFL Alumni Health, targets support for patients starting GLP‑1 therapy, and aligns with a mental health software TAM cited at $6.3 billion (2025) growing to $18.1 billion (2033).
Positive
- Strategic investment completed in a San Francisco mental health AI startup
- Integration of EinsteinRx AI with PharmacyChain to boost patient engagement
- Partnership expansion with Tollo Health and NFL Alumni Health to widen touchpoints
Negative
- None.
News Market Reaction – WGRX
On the day this news was published, WGRX gained 0.31%, reflecting a mild positive market reaction. Argus tracked a peak move of +25.1% during that session. Argus tracked a trough of -5.2% from its starting point during tracking. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $72K to the company's valuation, bringing the market cap to $23M at that time.
Data tracked by StockTitan Argus on the day of publication.
Previously announced partnership with Tollo Health subsidiary TolloCare adding telehealth service offering to drive Wellgistics Pharmacy prescription drug dispending of GLP-1 drugs and promote patient engagement via mental health AI software solution for compliance and to promote lifestyle changes
TAMPA, FL / ACCESS Newswire / February 18, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX), a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence ('AI') platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™, today announced that it has completed a strategic investment in a San Francisco-based mental health AI startup on the cusp of launching its service following successful beta testing. The investment fortifies the Company's strategic partnership with Tollo Health that was expanded to support Wellgistics' partnership with NFL Alumni Health.
Wellgistics is increasing its focus on patient engagement to help improve prescription drug compliance, promote complementary healthcare products such as medical food Forzet® that helps improve muscle maintenance via mitochondrial biogenesis, as well as further entrench itself within its Wellgistics Pharmacy Network as local pharmacy outlets become touchpoints to provide additional products, services and support for patients. By combining digital engagement with local physical pharmacy outlets, Wellgistics aims to provide unique support for patients throughout their healthcare journey, especially patients who are initiating GLP-1 drug treatment and need assistance managing potential side effects.
According to SNS Insider, the mental health software is expected to grow from
About Wellgistics Health, Inc.
Wellgistics Health (NASDAQ:WGRX) is a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™ to optimize the prescription drug dispending journey. Its integrated platform connects 6,500+ pharmacies (the "Wellgistics Pharmacy Network") and 200+ manufacturers, offering wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services such as eligibility, adherence, onboarding, prior authorization, and cash-pay fulfillment as needed to optimize patient access. Wellgistics provides end-to-end solutions designed to restore access, transparency, and trust in the U.S. prescription drug market for independent pharmacies.
For more information, visit www.wellgisticshealth.com.
Forward-Looking Statements
This press release contains forward‑looking statements within the meaning of the federal securities laws, including, without limitation, statements regarding the parties' plans to negotiate definitive agreements, potential implementation, adoption, performance, revenue sharing, and other anticipated benefits of the contemplated collaboration. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including those described in DataVault AI, Inc.'s and Wellgistics Health, Inc.'s filings with the SEC. Forward‑looking statements speak only as of the date hereof, and neither company undertakes any obligation to update them except as required by law. Additional factors are discussed in Wellgistics Health's filings with the SEC, available at www.sec.gov.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction, and there shall be no sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.
Wellgistics Media & Investor Contact
Media:
media@wellgisticshealth.com
Investor Relations:
IR@wellgisticshealth.com
SOURCE: Wellgistics Health, Inc.
View the original press release on ACCESS Newswire
FAQ
What did Wellgistics (WGRX) announce on February 18, 2026 about mental health AI?
How does the WGRX investment tie into Wellgistics' existing platforms EinsteinRx and PharmacyChain?
What partnerships did Wellgistics (WGRX) cite in support of the mental health AI investment?
How will the WGRX move affect patients starting GLP‑1 drug treatments?
What market opportunity did Wellgistics (WGRX) reference for mental health software and its timeline?
